百健
BIIB
232.65
-2.70
-1.15%
百健
US · BIIB
#623 按市值排名
上市于 1970
232.65
-2.70
-1.15%
实时 - 追踪5344个代码 - 心跳于570秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了7家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 97.80% -0.06pp
- 机构数量
- 1,267 -7
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund83.86%
Hedge Fund4.01%
Public Company3.52%
Government Pension Fund2.95%
Sovereign Wealth Fund1.80%
Private Company0.81%
VC/PE Fund0.25%
Individual/Insider0.21%
Insurance Company0.20%
Other2.41%
主要股东 截至 2026-06-30
FMR
11.26% · 16.63M 股
BlackRock
10.82% · 15.99M 股
PRIMECAP Management Company
10.26% · 15.15M 股
Vanguard Capital Management, LLC
7.09% · 10.48M 股
State Street Global Advisors
4.97% · 7.34M 股
Vanguard Portfolio Management, LLC
4.47% · 6.60M 股
Geode Capital Management, LLC
3.01% · 4.45M 股
Wellington Management Group
2.11% · 3.12M 股
Norges Bank Investment Management
1.75% · 2.58M 股
UBS Asset Management
1.55% · 2.29M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 35次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Susan Alexander | Chief Legal Officer | 0.04% |
| Christopher Viehbacher | Chief Executive Officer | 0.02% |
| Caroline Dorsa | Independent Chairperson | 0.02% |
| Michael McDonnell | Chief Financial Officer | 0.02% |
| Eric Rowinsky | Independent Director | 0.02% |
| Ginger Gregory | Executive Vice President | 0.02% |
| Nicole Murphy | Head of Pharmaceutical Operations & Technology | 0.01% |
| Stephen A. Sherwin | Independent Director | 0.01% |
| Robin Kramer | Chief Accounting Officer | 0.01% |
| Rachid Izzar | Head of Global Product Strategy & Commercialization | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Sale | -8 | $219.88 |
| 2026-10-01 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Retained | +19 | -- |
| 2026-09-30 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Other Derivative Acquisition | +985 | -- |
| 2026-08-31 | Michael Parini | Chief Legal Officer | Other Derivative Acquisition | +7,405 | -- |
| 2026-08-03 | Lloyd Minor | Directors | Open Market Disposition | -1,186 | $200.96–203.34 |
| 2026-08-03 | Lloyd Minor | Directors | Intent to Sell (Form 144) | -593 | $200.96 |
| 2026-08-02 | Lloyd Minor | Directors | Intent to Sell (Form 144) | -593 | $203.34 |
| 2026-06-08 | Stephen A. Sherwin | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | William Hawkins | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Eric Rowinsky | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Maria Freire | Independent Director | Other Acquisition | +2,005 | -- |
| 2026-06-08 | Lloyd Minor | Directors | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Monish Patolawala | Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Menelas Nicolas Pangalos | Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Menelas Nicolas Pangalos | Director | Derivative Exercise and Retained | +2,370 | -- |
| 2026-06-08 | Jesus Mantas | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Susan Langer | Director | Other Acquisition | +1,505 | -- |
| 2026-04-30 | Adam Keeney | Executive VP & Head of Corporate Development | Derivative Exercise and Sale | -455 | $187.06 |
| 2026-04-30 | Adam Keeney | Executive VP & Head of Corporate Development | Derivative Exercise and Retained | +484 | -- |
| 2026-03-31 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Sale | -54 | $183.78 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
百健 讨论区 0 条评论